Loading clinical trials...

Analysis of the Enteric Nervous System Using Colonic Biopsies | Clinical Trials | Clareo Health

COMPLETEDNA

Analysis of the Enteric Nervous System Using Colonic Biopsies

Analysis of the Enteric Nervous System Using Colonic Biopsies: a Useful Biomarker for the Differential Diagnosis of Parkinsonian Syndromes?

NCT01353183•Nantes University Hospital

View on ClinicalTrials.gov

Summary

The aim of this project is to develop an original biomarker for Parkinson's disease (PD) and other parkinsonian syndromes (multiple system atrophy and progressive supranuclear palsy) based upon the detection of pathological alpha-synuclein species in routine colonoscopic biopsies.

Eligibility

Age

50 - 80 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patients
•Patients aged 50-80 year old, both genders
•Parkinson's disease patients
•Multiple system atrophy patients
•Progressive supranuclear palsy patients
•Controls: patient at risk of colic cancer for whom a colonoscopy is required
•Patients who signed the informed consent
•Controls
•Patients aged 50 to 80 year-old for whom a rectosigmoidoscopy or a colonoscopy is required for colorectal screening
•Patients who signed the informed consent
+1 more criteria

Exclusion Criteria

•Patients
•Colonic disorder (except non-complicated diverticular disease)
•Other neurological disorder than parkinsonism
•Patients treated with either platelet antiaggregants, anticoagulants or with a known coagulation disorder
•Patients with a cognitive impairment that preclude them from understanding the informed consent
•Patients placed under legal guardianship
•Controls
•Neurodegenerative disorders such as Parkinson's disease, Alzheimer's disease or other dementia, amyotrophic lateral sclerosis...
•Functional bowel disorder such as irritable bowel syndrome
•Patients with a cognitive impairment that preclude them from understanding the informed consent

Locations (1)

Nantes University Hospital

Nantes, France

Key Dates

Start Date

November 1, 2010

Primary Completion Date

November 1, 2012

Completion Date

November 1, 2012

Last Updated

September 19, 2013

Enrollment

ACTUAL participants

Conditions

Parkinson's DiseaseMultiple System AtrophyProgressive Supranuclear Palsy

Interventions

colonoscopy or rectosigmoidoscopy

PROCEDURE

Research Into the Safety of a New Agent (VT-5006) in People With and Without Parkinson's Disease

NCT07310264

Healthy Volunteers (HV)Parkinson's Disease (PD)

View study

RECRUITINGNA

Deep Brain Stimulation Therapy in Movement Disorders

NCT02119611

Parkinson's Disease

View study

RECRUITINGPHASE1

[18F]F-DOPA Imaging in Patients With Autonomic Failure

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 19, 2013Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Analysis of the Enteric Nervous System Using Colonic Biopsies

Inclusion Criteria

Exclusion Criteria

Research Into the Safety of a New Agent (VT-5006) in People With and Without Parkinson's Disease

Deep Brain Stimulation Therapy in Movement Disorders

[18F]F-DOPA Imaging in Patients With Autonomic Failure

Adaptive DBS Algorithm for Personalized Therapy in Parkinson's Disease (ADAPT-PD) China Study

A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

Effect of Striatal Temporal Interference Stimulation on Language Processing in Neurodegenerative Diseases